×
About 528 results

ALLMedicine™ Waldenstrom Macroglobulinemia Center

Research & Reviews  152 results

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM...
https://clinicaltrials.gov/ct2/show/NCT00923507

Jun 24th, 2022 - The purpose of this protocol is to collect blood, tissue (bone marrow and lymph node biopsies) and/or imaging studies (PET and CT scans) from patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymph...

Vaccine Responses in Patients With B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05170399

Jun 24th, 2022 - Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) [follicular lymphoma (FL), mantle cell lymp...

Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.
https://doi.org/10.1200/JCO.22.00495
Journal of Clinical Oncology : Official Journal of the Am... Gertz MA

Jun 15th, 2022 - With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past ...

Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rar...
https://doi.org/10.1016/j.clml.2022.04.008
Clinical Lymphoma, Myeloma & Leukemia; Kline KAF, Lee ST et. al.

May 8th, 2022 - Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rare transformation or unhappy coincidence?|2022|Kline KAF,Lee ST,Law JY,Kallen M,|

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02952508

May 6th, 2022 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

see more →

Clinicaltrials.gov  24 results

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM...
https://clinicaltrials.gov/ct2/show/NCT00923507

Jun 24th, 2022 - The purpose of this protocol is to collect blood, tissue (bone marrow and lymph node biopsies) and/or imaging studies (PET and CT scans) from patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymph...

Vaccine Responses in Patients With B Cell Malignancies
https://clinicaltrials.gov/ct2/show/NCT05170399

Jun 24th, 2022 - Description: This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) [follicular lymphoma (FL), mantle cell lymp...

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT02952508

May 6th, 2022 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT01198067

Apr 27th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity profile of pomalidomide in pat...

A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies
https://clinicaltrials.gov/ct2/show/NCT03328078

Apr 7th, 2022 - This is a multi-center, open-label trial to evaluate oral administration of emavusertib (CA-4948) in adult patients with relapsed/refractory hematologic malignancies. Part A will evaluate escalating doses of emavusertib either as monotherapy (Part...

see more →

News  31 results

When to Treat as Important as Which Drug to Use in WM
https://www.medscape.com/viewarticle/961877

Oct 29th, 2021 - When to initiate treatment is as important as what to use for the treatment of patients newly diagnosed with Waldenstrom macroglobulinemia (WM), a leading expert in the disease emphasizes. "We have to be very careful not to tell patients they have...

Looking Ahead in Treating Follicular Lymphoma
https://www.onclive.com/view/looking-ahead-in-treating-follicular-lymphoma

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Let’s talk about BTK [Bruton tyrosine kinase] inhibitors in follicular lymphoma. I think they’re commonly prescribed, more commonly than you would imagine in the relapsed setting in patients with that. That’s...

FDA Approval in Waldenstrom Macroglobulinemia, Priority Review and sNDA in Multiple Myeloma, and More
https://www.onclive.com/view/fda-approval-in-waldenstrom-macroglobulinemia-priority-review-and-snda-in-multiple-myeloma-and-more

Apr 2nd, 2021 - Today- An FDA approval in Waldenstrom macroglobulinemia, a priority review in multiple myeloma, a new drug application submitted in myeloma, European approvals of chimeric antigen receptor T-cell therapies, and a US Preventative Task Force scre...

Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia
https://www.medscape.com/viewarticle/944782

Jan 27th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...

Ofatumumab to Be Available Through a Patient Access Program for CLL
https://www.onclive.com/view/ofatumumab-to-be-available-through-a-patient-access-program-for-cll

Dec 20th, 2020 - Patients with chronic lymphocytic leukemia (CLL) who are being treated with ofatumumab (Arzerra) will soon have to get their therapy through an oncology patient access program, as Novartis, the manufacturer, will no longer be selling the drug comm...

see more →

Patient Education  4 results see all →